NCT03607890 - Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 16, 2018

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions

Refractory MSI - H Solid Tumors Prior of PD-(L) 1 TherapyMSI-H Tumors

Interventions

DRUG

Nivolumab

Patients will receive treatment every 28 days for up to 2 years. Nivolumab will be administered IV on day 1 (28 day cycle).

DRUG

Relatlimab

Patients will receive treatment every 28 days up to 2 years. Relatlimab will be administered IV on day 1 (28 day cycle).

DRUG

Nivolumab

Patients will receive treatment every 28 days for up to 2 years. Nivolumab will be administered IV on day 1 (28 day cycle).

DRUG

Relatlimab

Patients will receive treatment every 28 days up to 2 years. Relatlimab will be administered IV on day 1 (28 day cycle).

DRUG

Nivolumab

Patients will receive treatment every 28 days for up to 2 years. Nivolumab will be administered IV on day 1 (28 day cycle).

DRUG

Relatlimab

Patients will receive treatment every 28 days up to 2 years. Relatlimab will be administered IV on day 1 (28 day cycle).

Trial Locations (2)

RECRUITING

Sidney Kimmel Comprehensive Cancer Center, Baltimore

RECRUITING

Cedars Sinai Medical Center, Los Angeles